(VIANEWS) – NORSKE SKOG (NSKOG.OL), AZERION (AZRN.AS), BOUVET (BOUV.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. NORSKE SKOG (NSKOG.OL)
32.1% sales growth and 8.63% return on equity
Norske Skog ASA engages in the production and sale of publication and packaging paper products in Norway, rest of Europe, North America, Australasia, Asia, and Africa. It operates in Publication paper Europe, Publication paper Australasia, and Packaging paper segments. The company offers newsprint paper products comprising standard newsprint and other papers; magazine papers, including super calendared and lightweight coated papers; and recycled containerboards. Its products are primarily used in newspapers and magazines, periodicals, catalogues, brochures, advertising materials, inserts/flyers, supplements, free-sheets, directories, direct mail, and books. Norske Skog ASA was founded in 1962 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, NORSKE SKOG has a trailing twelve months EPS of kr5.27.
PE Ratio
NORSKE SKOG has a trailing twelve months price to earnings ratio of 7.2. Meaning, the purchaser of the share is investing kr7.2 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.63%.
Sales Growth
NORSKE SKOG’s sales growth for the next quarter is 32.1%.
Yearly Top and Bottom Value
NORSKE SKOG’s stock is valued at kr37.94 at 07:20 EST, way below its 52-week high of kr48.40 and way above its 52-week low of kr32.50.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Nov 20, 2023, the estimated forward annual dividend rate is 0.67 and the estimated forward annual dividend yield is 1.74%.
More news about NORSKE SKOG.
2. AZERION (AZRN.AS)
10.7% sales growth and 23.87% return on equity
Azerion Group N.V. operates a digital entertainment and media platform in the Netherlands, Germany, France, Great Britain, Ireland, Italy, other Nordic and European countries, the United States, the United Arab Emirates, and internationally. The company operates in two segments, Platform and Premium Games. Its integrated platform offers technology solutions to automate the purchase and sale of digital advertising inventory for advertisers, publishers, and game creators, as well as to develop, publish, distribute, and operate online social and casual games, and digital content. The company also operates Hawk, a digital advertising technology platform. Azerion Group N.V. was founded in 2013 and is headquartered in Schiphol-Rijk, the Netherlands.
Earnings Per Share
As for profitability, AZERION has a trailing twelve months EPS of €0.17.
PE Ratio
AZERION has a trailing twelve months price to earnings ratio of 8.41. Meaning, the purchaser of the share is investing €8.41 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.87%.
Moving Average
AZERION’s value is under its 50-day moving average of €1.56 and way under its 200-day moving average of €1.72.
Sales Growth
AZERION’s sales growth is 6.5% for the ongoing quarter and 10.7% for the next.
More news about AZERION.
3. BOUVET (BOUV.OL)
9.7% sales growth and 60.9% return on equity
Bouvet ASA provides IT and digital communication consultancy services for public and private sector companies in Norway, Sweden, and internationally. The company was incorporated in 1995 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, BOUVET has a trailing twelve months EPS of kr3.14.
PE Ratio
BOUVET has a trailing twelve months price to earnings ratio of 20.45. Meaning, the purchaser of the share is investing kr20.45 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 60.9%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
BOUVET’s EBITDA is 40.45.
Sales Growth
BOUVET’s sales growth is 12.3% for the present quarter and 9.7% for the next.
Volume
Today’s last reported volume for BOUVET is 41712 which is 5.06% below its average volume of 43939.
Yearly Top and Bottom Value
BOUVET’s stock is valued at kr64.20 at 07:20 EST, below its 52-week high of kr70.00 and way higher than its 52-week low of kr52.00.
More news about BOUVET.
4. SANOFI (SAN.PA)
7.4% sales growth and 5.82% return on equity
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, SANOFI has a trailing twelve months EPS of €4.3.
PE Ratio
SANOFI has a trailing twelve months price to earnings ratio of 21.15. Meaning, the purchaser of the share is investing €21.15 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.82%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on May 13, 2024, the estimated forward annual dividend rate is 3.76 and the estimated forward annual dividend yield is 3.75%.
Volume
Today’s last reported volume for SANOFI is 1839940 which is 37.38% above its average volume of 1339290.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is a negative 5.2% and positive 0.8% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 7.5%, now sitting on 47.08B for the twelve trailing months.
More news about SANOFI.
5. VERALLIA (VRLA.PA)
6% sales growth and 29.81% return on equity
Verallia Société Anonyme manufactures and sells glass packaging products for beverages and food products worldwide. It provides bottles for still and sparkling wines, spirits, beers, soft drinks, and oils. The company offers jars for baby food, dairy products, jams, honey, spreads, condiments, sauces, and preserves. Verallia Société Anonyme was founded in 1827 and is based in Courbevoie, France.
Earnings Per Share
As for profitability, VERALLIA has a trailing twelve months EPS of €4.01.
PE Ratio
VERALLIA has a trailing twelve months price to earnings ratio of 8.99. Meaning, the purchaser of the share is investing €8.99 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.81%.
More news about VERALLIA.
